Korean Circulation Journal

  • 제54권10호
  • /
  • Pages.636-650
  • /
  • 2024
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

A Single Center Experience of Pulmonary Arterial Hypertension Management in Korea: A 25-Year Comparative Analysis Following the Introduction of Targeted Therapy

  • Ji Hyun Cha (Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Shin Yi Jang (Pulmonary Hypertension Center, Heart Vascular Stroke Institute, Samsung Medical Center) ;
  • Jinyoung Song (Pulmonary Hypertension Center, Heart Vascular Stroke Institute, Samsung Medical Center) ;
  • I-Seok Kang (Pulmonary Hypertension Center, Heart Vascular Stroke Institute, Samsung Medical Center) ;
  • June Huh (Pulmonary Hypertension Center, Heart Vascular Stroke Institute, Samsung Medical Center) ;
  • Taek Kyu Park (Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jeong Hoon Yang (Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Seung Woo Park (Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Hojoong Kim (Pulmonary Hypertension Center, Heart Vascular Stroke Institute, Samsung Medical Center) ;
  • Duk-Kyung Kim (Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Sung-A Chang (Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2023.11.28
  • 심사 : 2024.06.04
  • 발행 : 2024.10.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: The transformation of pulmonary arterial hypertension (PAH) treatment in Korea, ushered by targeted therapy's advent, prompted our analysis of baseline attributes, treatment trends, and survival shifts within our single-center registry. Methods: We examined 230 patients (72.6% female, mean age 40.6±17.4 years) diagnosed and/or treated between 1980 and 2021 in our PAH clinic. Given targeted therapy's introduction and active use since 2007, we compared diagnostic classification, demographics, and treatment patterns at that juncture. Survival analysis encompassed PAH types and the overall population. For historical survival comparison, 50 non-registry patients were retrospectively added, and age-sex matching enabled pooled analysis. Results: Congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) constituted the largest subset (43.0%), trailed by connective tissue disease-associated PAH (CTD-PAH, 29.6%) and idiopathic PAH (IPAH, 19.1%). Post-2007, CTD-PAH proportions surged, notably with an elevated initiation rate of targeted therapy (95.4%). Overall survival rates at 1, 5, and 10 years stood at 91.3%, 77.4%, and 65.8%, respectively, with CHD-PAH exhibiting superior survival to idiopathic or CTD-PAH. Age-sex matching analysis indicated survival disparities between those starting immediate targeted therapy vs. conservative treatment upon diagnosis, especially driven by IPAH. Conclusions: In the post-introduction of the targeted therapy era, patients with PAH promptly started treatment right away, and higher survival rates of patients who started initial PAH-targeted therapy were demonstrated. The transition towards early treatment initiation might have likely contributed to the elevated survival rates observed in Korea's PAH patient cohort.

키워드

참고문헌

  1. Hassoun PM. Pulmonary arterial hypertension. N Engl J Med 2021;385:2361-76. https://doi.org/10.1056/NEJMra2000348
  2. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63. https://doi.org/10.1161/CIRCULATIONAHA.109.911818
  3. Galie N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J 2019;53:1802148.
  4. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43:3618-731. https://doi.org/10.1093/eurheartj/ehac237
  5. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev 2012;21:8-18. https://doi.org/10.1183/09059180.00008211
  6. Anderson JJ, Lau EM. Pulmonary hypertension definition, classification, and epidemiology in Asia. JACC Asia 2022;2:538-46. https://doi.org/10.1016/j.jacasi.2022.04.008
  7. Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 2011;140:301-9. https://doi.org/10.1378/chest.10-2327
  8. Ogawa A, Satoh T, Tamura Y, Fukuda K, Matsubara H. Survival of Japanese patients with idiopathic/heritable pulmonary arterial hypertension. Am J Cardiol 2017;119:1479-84. https://doi.org/10.1016/j.amjcard.2017.01.015
  9. Chung WJ, Park YB, Jeon CH, et al. Baseline characteristics of the Korean registry of pulmonary arterial hypertension. J Korean Med Sci 2015;30:1429-38. https://doi.org/10.3346/jkms.2015.30.10.1429
  10. Kang KY, Jeon CH, Choi SJ, et al. Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry. Int J Rheum Dis 2017;20:1227-36. https://doi.org/10.1111/1756-185X.12645
  11. Jang SY, Kim EK, Huh J, et al. A retrospective population-based survival study of idiopathic pulmonary arterial hypertension in Korea. J Korean Med Sci 2022;37:e80.
  12. Seung J, Park HJ. Current trends and movements in managing pulmonary arterial hypertension in Korea. Korean Circ J 2023;53:328-30. https://doi.org/10.4070/kcj.2023.0039
  13. Jang AY, Shin MS. Echocardiographic screening methods for pulmonary hypertension: a practical review. J Cardiovasc Imaging 2020;28:1-9. https://doi.org/10.4250/jcvi.2019.0104
  14. Jang AY, Lee HH, Lee H, Kim HC, Chung WJ. Epidemiology of PAH in Korea: an analysis of the national health insurance data, 2002-2018. Korean Circ J 2023;53:313-27. https://doi.org/10.4070/kcj.2022.0231
  15. Hendriks PM, Staal DP, van de Groep LD, et al. The evolution of survival of pulmonary arterial hypertension over 15 years. Pulm Circ 2022;12:e12137.
  16. Boucly A, Savale L, Jais X, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2021;204:842-54. https://doi.org/10.1164/rccm.202009-3698OC
  17. Chang KY, Duval S, Badesch DB, et al. Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry. J Am Heart Assoc 2022;11:e024969.
  18. Medrek S, Sahay S, Zhao C, Selej M, Frost A. Impact of race on survival in pulmonary arterial hypertension: results from the REVEAL registry. J Heart Lung Transplant 2020;39:321-30. https://doi.org/10.1016/j.healun.2019.11.024
  19. Kozu K, Sugimura K, Ito M, et al. Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. Int J Cardiol 2020;300:228-35. https://doi.org/10.1016/j.ijcard.2019.11.139
  20. Tamura Y, Kumamaru H, Satoh T, et al. Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension. Circ J 2017;82:275-82.
  21. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7. https://doi.org/10.1161/01.CIR.70.4.580
  22. Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007;132:373-9. https://doi.org/10.1378/chest.06-2913
  23. Quan R, Zhang G, Yu Z, et al. Characteristics, goal-oriented treatments and survival of pulmonary arterial hypertension in China: insights from a national multicentre prospective registry. Respirology 2022;27:517-28. https://doi.org/10.1111/resp.14247
  24. Kang BJ, Lee SD, Oh YM, Lee JS. Improved survival of Korean patients with idiopathic pulmonary arterial hypertension after the introduction of targeted therapies. Heart Lung 2014;43:561-8. https://doi.org/10.1016/j.hrtlng.2014.07.003
  25. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:78S-92S. https://doi.org/10.1378/chest.126.1_suppl.78S
  26. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2014;35:716-24. https://doi.org/10.1093/eurheartj/eht072